Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 117-125 , January 2010

White blood cell count and renin–angiotensin system inhibitors for the risk of cancer in type 2 diabetes

  • Xilin Yang

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • Corresponding Author InformationCorresponding author at: Room 507, Li Ka Shing Institute of Health Sciences, c/o Department of Medicine and Therapeutics, The Prince of Wales Hospital, Shatin, Hong Kong, SAR, China. Tel.: +852 3763 6052; fax: +852 2637 3852.
    • ,
  • Ronald C.W. Ma

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Wing Yee So

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Gary T.C. Ko

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Alice P.S. Kong

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Hailu Zhao

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Gang Xu

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Peter C.Y. Tong

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • ,
  • Juliana C.N. Chan

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China
    • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China

Received 12 May 2009 ,Revised 14 October 2009 ,Accepted 22 October 2009.

References 

  1. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(January (2)):194–202
  2. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J. Natl. Cancer Inst. 2006;98(January (2)):135–138
  3. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer. 2005;92(June (11)):2076–2083
  4. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int. J. Cancer. 2006;118(April (8)):2105–2109
  5. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res. Treat. 2006;98(March (3)):349–356
  6. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(July (7)):1365–1374
  7. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am. J. Epidemiol. 2005;161(January (2)):147–152
  8. Yang X, So WY, Ko GT, Ma RC, Kong AP, Chow CC, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008;179(5):427–437
  9. Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q, et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr. Relat. Cancer. 2008;15(June (2)):597–607
  10. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol. Rep. 2006;15(January (1)):155–159
  11. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, et al. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 2004;130(October (10)):567–573
  12. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(November (9)):2462–2470
  13. Sjoberg T, Garcia Rodriguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin. Gastroenterol. Hepatol. 2007;5(October (10)):1160-6 e1
  14. Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr. Pharm. Des. 2003;9(9):723–735
  15. Gage JR, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation. 2004;11(3):173–180
  16. Finn OJ. Cancer immunology. N. Engl. J. Med. 2008;358(June (25)):2704–2715
  17. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch. Intern. Med. 2006;166(January (2)):188–194
  18. Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol. Biomarkers Prev. 2004;13(June (6)):1052–1056
  19. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med. 1993;10:371–377
  20. Information Services Department of Hong Kong, Hong Kong: the Facts. Public Health, Available at: http://wwwinfogovhk/hkfacts/pubhealth-epdf Accessed on 19 May 2006. 2005 October.
  21. Yang XL, So WY, Kong AP, Clarke P, Ho CS, Lam CW, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia. 2006;49(October (10)):2299–2308
  22. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 2006;17(October (10)):2937–2944
  23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18(June (6)):499–502
  24. Harrell F. Regression Modelling Strategies with applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Spinger-Varlag New York, Inc.; 2001;
  25. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat. Med. 1989;8(May (5)):551–561
  26. Ahlbom A, Alfredsson L. Interaction: a word with two meanings creates confusion. Eur. J. Epidemiol. 2005;20(7):563–564
  27. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur. J. Epidemiol. 2005;20(7):575–579
  28. Kalilani L, Atashili J. Measuring additive interaction using odds ratios. Epidemiol. Perspect. Innov. 2006;3:5
  29. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann. Epidemiol. 2007;17(March (3)):227–236
  30. Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care. 2009;32(October (10)):1826–1832
  31. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am. J. Epidemiol. 1999;150(August (4)):327–333
  32. Rassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N. Engl. J. Med. 2006;355(August (8)):799–808
  33. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J. Hypertens. 2008;26(April (4)):622–629
  34. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112(February (4)):748–757
  35. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J. Natl. Cancer Inst. 2008;100(September (17)):1223–1232
  36. The ADVANCE Collaborative Group . Intensive Blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358(June (24)):2560–2572
  37. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell Endocrinol. 2009;302(April (2)):128–139
  38. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur. Heart J. 2001;22(November (22)):2075–2084
  39. Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, et al. Additive interaction between renin–angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes. 2009;58(April (7)):1518–1525

PII: S0168-8227(09)00460-4

doi: 10.1016/j.diabres.2009.10.012

Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 117-125 , January 2010

Article Tools

* Image Usage & Resolution